iShares Biotechnology ETF
957 hedge funds and large institutions have $6.93B invested in iShares Biotechnology ETF in 2025 Q4 according to their latest regulatory filings, with 217 funds opening new positions, 274 increasing their positions, 220 reducing their positions, and 45 closing their positions.
382% more first-time investments, than exits
New positions opened: 217 | Existing positions closed: 45
71% more funds holding in top 10
Funds holding in top 10: 7 → 12 (+5)
50% more capital invested
Capital invested by funds: $4.63B → $6.93B (+$2.3B)
25% more repeat investments, than reductions
Existing positions increased: 274 | Existing positions reduced: 220
19% more funds holding
Funds holding: 804 → 957 (+153)
1.77% more ownership
Funds ownership: 80.09% → 81.85% (+1.8%)
1% less call options, than puts
Call options by funds: $257M | Put options by funds: $260M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$247M |
| 2 |
Two Sigma Investments
New York
|
+$229M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$190M |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$120M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$107M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$218M |
| 2 |
JP Morgan Chase
New York
|
-$116M |
| 3 |
BCM
Bronte Capital Management
Bondi Junction,
Australia
|
-$34M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$28.9M |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
-$28.3M |
IBB Hedge Fund Activity: Q4 2025 in Review
957 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2025, worth a combined $6.93B — up 50% from $4.63B a quarter earlier.
Buyers outnumbered sellers: 217 funds opened new IBB positions and 45 closed out — a net gain of 172 holders — while 274 added to existing stakes and 220 trimmed.
The largest buyer was Citigroup, adding an estimated $247M. The largest seller was Goldman Sachs, cutting an estimated $218M.
- 957 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2025, up from 804 in Q3 2025.
- Funds reported $6.93B of iShares Biotechnology ETF stock for Q4 2025, up 50% quarter-over-quarter.
- 217 funds opened new iShares Biotechnology ETF positions in Q4 2025 and 45 closed out, a net change of +172 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2025 was Citigroup, an estimated $247M added.
- The largest iShares Biotechnology ETF seller in Q4 2025 was Goldman Sachs, an estimated $218M sold.
Based on aggregated 13F filings for Q4 2025.